Cybin Inc. Common Shares CYBN 深 沪
等待开盘 01-22 09:30:00 美东时间
8.28
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 8.28
- 总市值 2.09亿
- 52周最高 10.7199
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.81
- 委 比 0.00%
- 总股本 2518.82万
- 历史最高 122.36
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.81
- 每 手 1
- 风险率 1.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rose sharply in pre-market a...
2025-12-31 19:14
Cybin Launches $100M At-The-Market Equity Program With Cantor Fitzgerald
Cybin Inc. (NYSE:CYBN) (Cboe Canada CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation
2025-12-31 04:36
Cybin To Voluntarily Transfer US Stock Listing From NYSE American To Nasdaq, Effective Jan. 5
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today
2025-12-18 20:35
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
2025-12-04 09:38
Guggenheim Maintains Buy on Cybin, Raises Price Target to $48
Guggenheim analyst Eddie Hickman maintains Cybin (AMEX:CYBN) with a Buy and raises the price target from $39 to $48.
2025-12-04 00:05
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
2025-11-21 15:50
Canaccord Genuity Maintains Buy on Cybin, Lowers Price Target to $45
Canaccord Genuity analyst Sumant Kulkarni maintains Cybin (AMEX:CYBN) with a Buy and lowers the price target from $70 to $45.
2025-11-21 00:02
Cybin Q2 EPS $(1.39) Misses $(1.09) Estimate
Cybin (AMEX:CYBN) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.09) by 27.52 percent. This is a 33.81 percent increase over losses of $(2.10) per share from the same
2025-11-13 20:27
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
2025-11-13 19:11
Cybin announces $175 million registered direct offering
Cybin (NYSE:CYBN) on Tuesday announced a registered direct offering of 22.2M common shares in the capital of the company and, in lieu of common shares to certain investors, pre-funded common share pur...
2025-10-28 20:24
